Irinox 40 Injection contains Irinotecan 40 mg, a potent anticancer medicine widely used in the treatment of colorectal cancer and various other malignancies as part of combination chemotherapy protocols. It helps inhibit the growth and multiplication of cancer cells by interfering with DNA replication processes that are essential for tumor development. The injection is administered under the supervision of oncology specialists and forms an important component of modern cancer treatment strategies.

Irinotecan belongs to the class of topoisomerase I inhibitors and works by disrupting DNA repair and replication within rapidly dividing cancer cells. This mechanism results in the accumulation of DNA damage, ultimately leading to cancer cell death and reduced tumor progression. Its proven efficacy has made it a key therapeutic option in the management of advanced and metastatic cancers, particularly gastrointestinal malignancies.

The injection is commonly prescribed for metastatic colorectal cancer and may also be used in the treatment of gastric cancer, pancreatic cancer, lung cancer, and other malignancies as determined by an oncology specialist. It is often administered in combination with other anticancer agents to enhance treatment outcomes and improve disease control. Careful monitoring during therapy is essential to maximize effectiveness and manage potential treatment-related adverse effects.

With the growing demand for advanced oncology therapies and targeted chemotherapy regimens, Irinox 40 Injection maintains strong relevance in the anticancer segment. Its established clinical utility, broad therapeutic applications, and inclusion in multiple oncology treatment protocols contribute to consistent market demand. The product offers significant business potential and long-term growth opportunities for retailers and distributors operating within the oncology pharmaceutical market.

Irinox 40 Injection may cause diarrhea, nausea, vomiting, abdominal pain, fatigue, weakness, loss of appetite, hair loss, and low blood cell counts. Bone marrow suppression, severe diarrhea, infections, anemia, bleeding tendencies, and allergic reactions may occur and require close medical supervision.

Irinox 40 Injection is indicated for the treatment of metastatic colorectal cancer, advanced colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, and other malignancies as determined by an oncology specialist. It helps control cancer cell growth and supports comprehensive chemotherapy treatment regimens.

This medication should be administered only by qualified healthcare professionals experienced in cancer chemotherapy. Regular monitoring of blood counts, liver function, kidney function, hydration status, and overall patient condition is essential during treatment. Patients should immediately report severe diarrhea, fever, unusual bleeding, persistent vomiting, breathing difficulties, or signs of infection. Treatment should always be individualized according to the patient's condition and response to therapy.

Store in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep the vial in its original packaging until use and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of deterioration.